文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气消化、代谢与肾脏急症

急性呼吸窘迫综合征随机试验中急性肾损伤的发生率与归因死亡率

Incidence of acute kidney injury and attributive mortality in acute respiratory distress syndrome randomized trials.
PubMed 文献 · Intensive Care Med · 2024-06-12
一句话结论ARDS随机试验中AKI总体发生率43.7%,归因90天超额死亡率15.4%,急性肾病归因90天超额死亡率28.4%。

本研究对20年间10项多中心随机对照试验进行个体患者数据汇总分析,纳入5148例ARDS患者,采用Super Learner集成技术结合时间依赖分析估计AKI调整风险,并用逆概率治疗加权估计归因死亡率。AKI总体发生率43.7%(n=2251),调整风险从ARMA试验的38.8%(95%CI 35.7–41.9%)到ROSE试验的55.8%(95%CI 51.9–59.6%)。37.1%的患者AKI快速恢复,近期试验恢复率显著更低(P<0.001)。AKI归因90天超额死亡率为15.4%(95%CI 12.8–17.9%),急性肾病归因90天超额死亡率为28.4%(95%CI 25.3–31.5%)。作者认为这些估计值对设计未来AKI防治临床试验至关重要。

要点

  • 5148例ARDS患者中AKI总体发生率为43.7%(n=2251)。
  • AKI调整风险从ARMA的38.8%(95%CI 35.7–41.9%)到ROSE的55.8%(95%CI 51.9–59.6%)。
  • 37.1%的患者AKI快速恢复,近期试验恢复率显著更低(P<0.001)。
  • AKI归因90天超额死亡率为15.4%(95%CI 12.8–17.9%),急性肾病归因90天超额死亡率为28.4%(95%CI 25.3–31.5%)。
  • AKI归因90天超额死亡率从ARMA的25.4%(95%CI 18.7–32%)降至FACTT的11.8%(95%CI 5.5–18%)后趋于稳定。

适用人群与场景

  • 纳入10项多中心随机对照试验中的ARDS患者,共5148例,试验跨20年。

研究设计与关键结果

  • 研究类型为个体患者数据汇总分析,纳入10项多中心随机对照试验、5148例ARDS患者,采用Super Learner集成技术结合时间依赖分析估计AKI调整风险,并用逆概率治疗加权估计归因死亡率。
  • AKI总体发生率为43.7%(n=2251);调整风险从ARMA的38.8%(95%CI 35.7–41.9%)到ROSE的55.8%(95%CI 51.9–59.6%)。
  • 37.1%的患者AKI快速恢复,近期试验恢复率显著更低(P<0.001)。
  • AKI归因90天超额死亡率为15.4%(95%CI 12.8–17.9%),从ARMA的25.4%(95%CI 18.7–32%)降至FACTT的11.8%(95%CI 5.5–18%)后趋于稳定。
  • 急性肾病归因90天总体超额死亡率为28.4%(95%CI 25.3–31.5%)。

证据类型、等级与局限

  • 证据类型:基于10项多中心随机对照试验的个体患者数据汇总分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些AKI发生率与归因死亡率估计值对设计未来AKI预防或治疗临床试验至关重要。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: The development of acute kidney injury (AKI) after the acute respiratory distress syndrome (ARDS) reduces the chance of organ recovery and survival. The purpose of this study was to examine the AKI rate and attributable mortality in ARDS patients.

METHODS: We performed an individual patient-data analysis including 10 multicenter randomized controlled trials conducted over 20 years. We employed a Super Learner ensemble technique, including a time-dependent analysis, to estimate the adjusted risk of AKI. We calculated the mortality attributable to AKI using an inverse probability of treatment weighting estimator integrated with the Super Learner.

RESULTS: There were 5148 patients included in this study. The overall incidence of AKI was 43.7% (n = 2251). The adjusted risk of AKI ranged from 38.8% (95% confidence interval [CI], 35.7 to 41.9%) in ARMA, to 55.8% in ROSE (95% CI, 51.9 to 59.6%). 37.1% recovered rapidly from AKI, with a significantly lower recovery rate in recent trials (P < 0.001). The 90-day excess in mortality attributable to AKI was 15.4% (95% CI, 12.8 to 17.9%). It decreased from 25.4% in ARMA (95% CI, 18.7 to 32%), to 11.8% in FACTT (95% CI, 5.5 to 18%) and then remained rather stable over time. The 90-day overall excess in mortality attributable to acute kidney disease was 28.4% (95% CI, 25.3 to 31.5%).

CONCLUSIONS: The incidence of AKI appears to be stable over time in patients with ARDS enrolled in randomized trials. The development of AKI remains a significant contributing factor to mortality. These estimates are essential for designing future clinical trials for AKI prevention or treatment.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Antonucci E, Garcia B, Chen D, et al. Incidence of acute kidney injury and attributive mortality in acute respiratory distress syndrome randomized trials. Intensive Care Med. 2024. PMID: 38864911. doi:10.1007/s00134-024-07485-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。